Skip to content

Arvinas ARVN Net Investment in Lease

Net Investment in Lease at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
Immunome logo
ImmunomeIMNM
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's net investment in lease?
Arvinas (ARVN) reported net investment in lease of $7.8M in Q1 2026.
How has Arvinas's net investment in lease changed year-over-year?
Arvinas's net investment in lease decreased by 21.2% year-over-year, from $9.9M to $7.8M.
What is the long-term trend for Arvinas's net investment in lease?
Over 5 years (2020 to 2025), Arvinas's net investment in lease has grown at a 32.6% compound annual growth rate (CAGR), from $2M to $8.2M.